Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Plasmacytoma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 13Dexamethasone 13Cyclosporine 12Whole-Body Irradiation 11fludarabine 10Exercise 10Antilymphocyte Serum 10Melphalan 9Busulfan 9Blood Specimen Collection 9Mycophenolic Acid 8Therapeutics 7Filgrastim 7Bortezomib 7Standard of Care 6Radiotherapy 6Behavior Therapy 6Acupuncture Therapy 6pomalidomide 5Specimen Handling 5Palliative Care 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Educational Status 5daratumumab 4Surveys and Questionnaires 4Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × CF regimen × Plasma cell × Clear all
NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡